Mohamad Zandian, Irene P. Chen, Siddappa N. Byrareddy, Danica Galonić Fujimori, Melanie Ott, Tatiana G. Kutateladze, Catching BETs by viruses. Biochimica et Biophysica Acta (BBA) – Gene Regulatory Mechanisms, 2022, https://doi.org/10.1016/j.bbagrm.2022.19485
Archives: Publications
Publications
SARS-CoV-2 hybrid immunity: silver bullet or silver lining?.
Suryawanshi, R., Ott, M. SARS-CoV-2 hybrid immunity: silver bullet or silver lining?. Nat Rev Immunol. 2022. https://doi.org/10.1038/s41577-022-00771-8
SIRT5 is a proviral factor that interacts with SARS-CoV-2 Nsp14 protein.
Walter M, Chen IP, Vallejo-Gracia A, Kim IJ, Bielska O, Lam VL, Hayashi JM, Cruz A, Shah S, Soveg FW, Gross JD, Krogan NJ, Jerome KR, Schilling B, Ott M, Verdin E.
PLoS Pathog. 2022 Sep 12;18(9):e1010811. doi: 10.1371/journal.ppat.1010811. PMID: 36095012; PMCID: PMC9499238.
Structure-function analysis of enterovirus protease 2A in complex with its essential host factor SETD3.
Peters CE, Schulze-Gahmen U, Eckhardt M, Jang GM, Xu J, Pulido EH, Bardine C, Craik CS, Ott M, Gozani O, Verba KA, Hüttenhain R, Carette JE, Krogan NJ.
Nat Commun. 2022 Sep 8;13(1):5282. doi: 10.1038/s41467-022-32758-3. PMID: 36075902; PMCID: PMC9453702.
NF-κB inhibitor alpha has a cross-variant role during SARS-CoV-2 infection in ACE2-overexpressing human airway organoids.
Simoneau CR, Chen PY, Xing GK, Khalid MM, Meyers NL, Hayashi JM, Taha TY, Leon KE, Ashuach T, Fontaine KA, Rodriguez L, Joehnk B, Walcott K, Vasudevan S, Fang X, Maishan M, Schultz S, Roose J, Matthay MA, Sil A, Arjomandi M, Yosef N, Ott M.
bioRxiv [Preprint]. 2022 Aug 2:2022.08.02.502100. doi: 10.1101/2022.08.02.502100. PMID: 35982664; PMCID: PMC9387123.
Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles.
Syed AM, Ciling A, Taha TY, Chen IP, Khalid MM, Sreekumar B, Chen PY, Kumar GR, Suryawanshi R, Silva I, Milbes B, Kojima N, Hess V, Shacreaw M, Lopez L, Brobeck M, Turner F, Spraggon L, Tabata T, Ott M, Doudna JA. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. Proc Natl Acad Sci U S A. 2022. doi: 10.1073/pnas.2200592119.
Taking cues from convalescence to improve vaccines against hepatitis C virus.
Sreekumar BK, Taha TY, Ott M.
J Clin Invest. 2022 Aug 1;132(15):e161819. doi: 10.1172/JCI161819. PMID: 35912856; PMCID: PMC9337820.
Tropism of SARS-CoV-2 for Human Cortical Astrocytes.
Andrews MG, Mukhtar T, Eze UC, Simoneau CR, Perez Y, Mostajo-Radji MA, Wang S, Velmeshev D, Salma J, Kumar GR, Pollen AA, Crouch EE, Ott M, Kriegstein AR.
doi: 10.1101/2021.01.17.427024.
Viral E Protein Neutralizes BET Protein-Mediated Post-Entry Antagonism of SARS-CoV-2.
Chen I, Longbotham J.E, McMahon S, Suryawanshi R, Carlson-Stevermer J, Gupta M, Zhang MY, Soveg F.W , Hayashi J.M , Taha T.H, Lam V.L, Li Y, Yu Z, Titus E.W, Diallo A, Oki J, Holden K, QCRG Structural Biology Consortium; Krogan N, Fujimori D, Ott MViral E Protein Neutralizes BET Protein-Mediated Post-Entry Antagonism of SARS-CoV-2. Cell Rep. 2022. doi: 10.1016/j.celrep.2022.111088. Epub 2022 Jun 27
Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination.
Suryawanshi RK, Chen IP, Ma T, Syed AM, Brazer N, Saldhi P, Simoneau CR, Ciling A, Khalid MM, Sreekumar B, Chen PY, Kumar GR, Montano M, Garcia-Knight MA, Sotomayor-Gonzalez A, Servellita V, Gliwa A, Nguyen J, Silva I, Milbes B, Kojima N, Hess V, Shacreaw M, Lopez L, Brobeck M, Turner F, Soveg FW, George AF, Fang X, Maishan M, Matthay M, Greene WC, Andino R, Spraggon L, Roan NR, Chiu CY, Doudna J, Ott M. Limited Cross-Variant Immunity after Infection with the SARS-CoV-2 Omicron Variant Without Vaccination. Nature. 2022. doi: 10.1038/s41586-022-04865-0.